Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
NCT ID: NCT04295811
Last Updated: 2023-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
470 participants
INTERVENTIONAL
2020-06-18
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE
NCT04293458
Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population
NCT05778851
Lucid Registry Study
NCT05965999
A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus
NCT02560623
Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers
NCT05688176
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is divided into a Run-In phase and an Efficacy phase. The assignment of a patient to one or the other of these two phases will be made based on two pieces of information: 1) the Final Study Diagnosis (as defined below) and 2) the current tally versus the pre-determined target number of patients already assigned to each of the subgroups (e.g., non-dysplastic Barrett's Esophagus (NDBE), high grade dysplasia {HGD\]) for each phase. Patients will first be enrolled into the Run-In phase subgroups. Only once the targeted enrollment for a given Run-In phase subgroup has been reached, subsequent patients with a particular diagnosis will be assigned to the appropriate Efficacy Phase subgroup, until the targeted total number is reached. Run In phase data will be maintained in a separate database from Efficacy phase data. Study conduct is identical in both phases; however, data from each phase will be segregated and analysis of each phase will be used solely for its predetermined purpose without any co-mingling of data. Once assigned, no patient, or their data, will be re-assigned or moved from being a Run-In phase patient to being an Efficacy phase patient, or from the Run-In phase database to the Efficacy phase database, or vice versa.
The Run-In phase will enroll the initial 60 short segment NDBE (also known as short segment Barrett's Esophagus \[SSBE\]) and 25 long segment NDBE (also known as long segment Barrett's Esophagus \[LSBE\]) Cases, the initial 10 low grade dysplasia \[LGD\] Cases, the initial 3 high grade dysplasia \[HGD\] Cases, and the initial 2 intramucosal adenocarcinoma \[IMC\] Cases, as well as the initial 100 Controls. The Efficacy phase will enroll 54 Cases each with a Final Study Diagnosis of NDBE, LGD, HGD, and IMC, and 54 Controls.
Run-In phase data will be used solely to derive the optimal numerical cutoffs by which to score mVIM and mCCNA1 (which are two genes where the methylated DNA changes are located) positivity or negativity. These cutoffs serve as the key inputs into an algorithm by which an overall EsoGuard result of positive versus negative is determined. The setting of these cutoffs will be done by Sponsor personnel with full access to all Run-In phase data; the goal will be to optimize overall EsoGuard assay sensitivity and specificity for its intended use as a screening test in the at-risk population. The assay, once validated and locked, will be used to analyze patients' distal esophageal cells obtained in both the Efficacy phase of this Case Control study as well as in a separate Screening study (PR-1039/EG-CL-101) to be conducted in parallel. Only Run-In phase data will be used to set cutoffs. The mVIM and mCCNA1 (i.e., genes with methylated DNA changes) cutoffs will be set and then the EsoGuard assay re validated and "locked", all before any Efficacy phase distal esophageal cells specimens collected from study patients will undergo EsoGuard analysis.
Sponsor personnel will have open access to all Run-In phase data during the enrollment of the Run-In phase in order to determine if the data from patients enrolled to date is sufficient to inform adequately the setting of cutoffs. If Sponsor so determines, it may elect to terminate enrollment in the Run-In phase early (i.e., prior to enrolling the 100 Cases and 100 Controls listed above). If early termination of the Run-In phase is elected, all patients enrolled subsequent to the date Sponsor makes this election will be entered into the Efficacy phase and such subsequent patients will count towards the Efficacy phase enrollment objectives.
As well, should Sponsor complete the intended Run-In phase enrollment of 100 Cases and 100 Controls but determine, upon its assessment of the resulting data, that data from additional Cases could improve the setting of cutoffs, Sponsor may decide to enroll up to 100 additional Run-In phase Cases. These 100 Cases may be in whatever distribution of disease Sponsor elects (i.e., ranging from NDBE through to IMC). In order to augment the Run-In phase patient counts, the Sponsor will set updated targets for enrollment of each Run-In phase subgroup and will assign patients to each Run-In subgroup to be augmented, based on patients' Final Study Diagnosis and on whether the updated subgroup target has been met. When each updated subgroup enrollment target has once again been met, subsequent patients with that subgroup diagnosis will be enrolled into the Efficacy phase.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EsoCheck and EsoGuard vs. EGD with or without biopsies
All subjects will undergo both the EsoGuard lab assay run on distal esophageal cells collected with EsoCheck (non-invasive esophageal cell sample collection) device followed by Esophagogastroduodenoscopy (EGD) with or without biopsies
EsoGuard (lab assay)
EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
Esophagogastroduodenoscopy
Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EsoGuard (lab assay)
EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
Esophagogastroduodenoscopy
Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Men aged 50 years and above
2. ≥5 years either of
* Gastroesophageal Reflux Disease (GERD) symptoms,
* GERD treated with proton pump inhibitor (PPI) therapy (whether symptom control is achieved or not), or
* any combination of treated and untreated periods, as long the cumulative total is at least 5 years
3. No solid foods eaten for at least 2 hours prior to EsoCheck procedure
4. One or more of the following:
* Caucasian race
* Current or past history of cigarette smoking
* Body mass index (BMI) of at least 30 kg/m2
* First-degree relative with Barrett's Esophagus (BE) or Esophageal Adenocarcinoma (EAC)
Cases:
1. Previous diagnosis of non-dysplastic Barrett's Esophagus (NDBE), low grade dysplasia (LGD), high grade dysplasia (HGD), and/or intramucosal adenocarcinoma (IMC)
2. Diagnosis by esophagogastroduodenoscopy (EGD) (with exception of NDBE) was within 4 months prior to study enrollment
3. Indicated for surveillance EGD or for therapeutic EGD
4. Able to provide, by day of study EGD, the original glass slide(s) of biopsy specimens from most recent prior EGD
Exclusion Criteria
2. On anti-coagulant drug(s) that cannot be temporarily discontinued
3. Known history of esophageal varices or esophageal stricture
4. Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula, and/or esophageal ulceration
5. History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
6. Oropharyngeal tumor
7. History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure
8. History of myocardial infarction or cerebrovascular accident within past 6 months
9. Any known lesion which, in the opinion of the endoscopist, obstructs greater than 25% of the esophageal lumen
10. Prior participation in PR-0139/EG-CL-101 (Lucid BE Screening Study)
11. Prior EGD during which a therapeutic procedure such as, but not limited to, ablation, cryotherapy or endoscopic mucosal resection, was performed for the treatment of BE and/or EAC
12. History of esophageal motility disorder
13. Currently implanted Linx device
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lucid Diagnostics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michelle McDermott
Role: STUDY_DIRECTOR
Lucid Diagnostics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lucid Investigative Site
Birmingham, Alabama, United States
Lucid Investigative Site
Orange, California, United States
Lucid Investigative Site
Aurora, Colorado, United States
Lucid Investigative Site
Englewood, Colorado, United States
Lucid Investigative Site
Washington D.C., District of Columbia, United States
Lucid Investigative Site
Jacksonville, Florida, United States
Lucid Investigative Site
Chicago, Illinois, United States
Lucid Investigative Site
Shreveport, Louisiana, United States
Lucid Investigative Site
Baltimore, Maryland, United States
Lucid Investigative Site
Boston, Massachusetts, United States
Lucid Investigative Site
Ann Arbor, Michigan, United States
Lucid Investigative Site
Flowood, Mississippi, United States
Lucid Investigative Site
St Louis, Missouri, United States
Lucid Investigative Site
Omaha, Nebraska, United States
Lucid Investigative Site
Lebanon, New Hampshire, United States
Lucid Investigative Site
New Hyde Park, New York, United States
Lucid Investigative Site
Rochester, New York, United States
Lucid Investigative Site
Chapel Hill, North Carolina, United States
Lucid Investigative Site
Portland, Oregon, United States
Lucid Investigative Site
Philadelphia, Pennsylvania, United States
Lucid Investigative Site
Philadelphia, Pennsylvania, United States
Lucid Investigative Site
Providence, Rhode Island, United States
Lucid Investigative Site
Charleston, South Carolina, United States
Lucid Investigative Site
Greenville, South Carolina, United States
Lucid Investigative Site
Knoxville, Tennessee, United States
Lucid Investigative Site
Nashville, Tennessee, United States
Lucid Investigative Site
Austin, Texas, United States
Lucid Investigative Site
Dallas, Texas, United States
Lucid Investigative Site
Houston, Texas, United States
Lucid Investigative Site
Salt Lake City, Utah, United States
Lucid Investigative Site
Richmond, Virginia, United States
Lucid Investigative Site
Richmond, Virginia, United States
Lucid Investigative Site
Amsterdam, , Netherlands
Lucid Investigative Site
Eindhoven, , Netherlands
Lucid Investigative Site
Groningen, , Netherlands
Lucid Investigative Site
Nieuwegein, , Netherlands
Lucid Investigative Site
Nijmegen, , Netherlands
Lucid Investigative Site
Rotterdam, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR-0138 / EG-CL-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.